1	Chinese medicine (Q-14) in the Treatment of Patients with Coronavirus		
2	Disease 2019 (COVID-19): A Single-center, Open label, Randomised		
3	Controlled Trial		
4	Authors:		
5	Jia Liu ^{b,1} , Wei Yang ^{b,1} , Yue Liu ^{c,1} , Cheng Lv ^{b,1} , Lianguo Ruan ^{d,1} , Chen Zhao ^{b,1} , Ruili		
6	Huo ^{a,1} , Xin Shen ^{e,1} , Qing Miao ^{c,1} , Wenliang Lv ^{f,1} , Hao Li ^{c,1} ,Huaxin Shi ^{a,1} , Lijie Hu ^{a,1} ,		
7	Zhixu Yang ^{c,1} , Li Zhang ^{c,1} , Bing Wang ^{c,1} , Guoju Dong ^{c,1} , Yongyue Xian ^{c,1} , Bin Li ^{c,1} ,		
8	Zhenqi Zhou ^{c,1} , Chunyan Xu ^{c,1} , Yingying Chen ^{c,1} , Yongjun Bian ^{f,1} , Jing Guo ^{f,1} , Jinliang		
9	Yang ^{f,1} , Jian Wang ^{f,1} , Wensheng Qi ^{f,1} , Suping Chen ^{f,1} , Yang Chen ^{f,1} , Bei Yan ^{f,1} , Wei		
10	Wang ^{f,1} , Jing Li ^{c,1} , Xiaolei Xie ^{c,1} , Ming Xu ^{c,1} , Jianxin Jiang ^{c,1} , Gang Wang ^{c,1} , Xiaodong		
11	Cong ^{c,1} , Haoning Zhu ^{c,1} , Jiaheng Shi ^{f,1} , Luxing Leng ^{f,1} , Dongxu Li ^{f,1} , Lanping Guo ^{g,1} , Luqi		
12	Huang ^{*a,h,1}		
13 14 15	a. China Academy of Chinese Medical Sciences, Beijing, China b. China Academy of Chinese Medical Sciences Institute of Basic research in Clinical Medicine, Beijing, China		
16 17 18	c. China Academy of Chinese Medical Sciences Xiyuan Hospital, Beijing, China d. Wuhan Jinyintan Hospital, Wuhan, Hubei, China e. China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica,		
19 20 21 22	Beijing, China f. China Academy of Chinese Medical Sciences Guanganmen Hospital, Beijing, China g. China Academy of Chinese Medical Sciences Chinese Materia Medica Resource Center Beijing, China		
23 24	h. China Center for Evidence-based Medicine of Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China		
25	*Corresponding author:		
26 27	Luqi Huang, Professor, China Center for Evidence-based Medicine of Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China		
28	<u>Tel: +86 64089838; fax: +86 64089838</u>		
29	E-mail: <u>huanglq@cacms.cn</u>		
30	¹ The authors contributed to this work equally;		
31	1 / 30		

32

ABSTRACT

- 33 **OBJECTIVE**
- 34 To evaluate the efficacy and safety of Chinese medicine (Q-14) plus standard care
- 35 compared with standard care alone in adult with coronavirus disease 2019
- 36 (COVID-19).
- 37 Study DESIGN
- 38 Single-center, open label, randomised controlled trial.
- 39 SETTING
- 40 Wuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020.
- 41 PARTICIPANTS
- 42 204 patients with laboratory confirmed COVID-19 were randomised in to treatment
- 43 group and control group, which was 102 patients each group.
- 44 INTERVENTIONS
- 45 In treatment group, Q-14 was administrated at 10g (granules), twice daily for 14 days
- and plus standard care. In control group, patients were given standard care alone for
- 47 14 days.
- 48 MAIN OUTCOME MEASURE
- The primary outcome was conversion time of SARS-CoV-2 viral assay. Adverse events
- 50 were analyzed in the safety population.
- 51 **RESULTS**
- 52 Among 204 patients, 195 were analyzed according to the intention to treat principle.
- 53 There were 149 patients (71 vs. 78 in treatment group and control group respectively)
- 54 turning to negative via SARS-CoV-2 viral assay. No statistically significance showed in
- 55 conversion time between treatment group and control group (FAS: Median (IQR):
- 56 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); Mean rank: 67.92 vs. 81.44; P=0.051.).
- 57 Time to recovery of fever was shorter in treatment group as compared in control
- 58 group. The disappearance rate of symptom in cough, fatigue, chest discomfort was
- 59 significantly higher in treatment group. In chest computed tomography (Chest CT)
- 60 examinations, overall evaluation of chest CT examination after treatment compared
- 61 with baseline showed more patients improved in treatment group .There were no
- 62 significant differences in the other outcomes.
- 63 CONCLUSION
- Administration of Q-14 on standard care for COVID-19 was useful for improvement of symptoms (such as fever, cough, fatigue and chest discomfort), while did not result in a significantly higher probability of negative conversion of SARS-CoV-2 viral assay. No serious adverse events were reported.
- 68 TRIAL REGISTRATION
- 69 ChiCTR2000030288
- 70
- 71

72

73 Keywords

74 COVID-19; Chinese medicine; efficacy; safety; Randomised Controlled Trial; Q-14 75 76 Abbreviations: CI, Confidence interval; CNMTCM-CACMS, China National Medical 77 Team of Traditional Chinese Medicine of China Academy of Chinese Medical Sciences; 78 CONSORT, Consolidated Standards of Reporting Trials;COVID-19, Coronavirus Disease 79 2019;CT, Computed tomography; ECMO, Extracorporeal membrane oxygenation; FAS, 80 Full Analysis Set; GCP, Good Clinical Practice; IQR, Interquartile range; 81 NHC-NATCM-China guidelines, National clinical practice guideline for COVID-19 in 82 China" developed by the National Health Commission and the National 83 Administration of TCM of the People's Republic of China; PPS, Per-protocol Set; RT-PCR, Reverse-transcription polymerase chain reaction; SCIO-China, State Council 84 85 Information Office of the People's Republic of China; TCM, Traditional Chinese 86 medicine; WHO, World Health Organization

87

88

89 INTRODUCTION

90 CoronaVirus Disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has resulted 91 in considerable morbidity and mortality in more than 200 countries, which has 92 become a major public health crisis on a global scale (Wang et al., 2020). By August 93 24, 2020, the number of confirmed cases of COVID-19 has reached more than 23 million, the total reported deaths now exceeds 800,000 globally, with rapid daily 94 95 increases in some countries (WHO, 2020). Information regarding the epidemiology and clinical features of COVID-19 (Wu et al., 2020; Chen et al., 2020) provides good 96 97 support for its clinical prevention and treatment, but many of the drugs previously 98 hailed as star drugs, such as remdesivir, favipiravir, lopinavir-ritonavir and 99 chloroquine or hydroxychloroquine have not shown ideal results in clinical trials, 100 even some of them has been found to have obvious toxic side effects (Wang et al., 101 2020; Tang et al. 2020). Scientists around the world are actively seeking potential 102 effective drugs or developing vaccine to treat COVID-19.

103

104 China quickly halted the spread of COVID-19 with strong containment measures (Li et 105 al., 2020). The strategy of integrated traditional Chinese medicine (TCM) with 106 western medicine plays an important role in the prevention and control of COVID-19 107 in China, more than 90% confirmed cases have received TCM therapy (SCIO-China, 108 2020). At the beginning of COVID-19, China National Medical Team of Traditional 109 Chinese Medicine of China Academy of Chinese Medical Sciences (CNMTCM-CACMS 110 Team) went to Wuhan to carry out integrated TCM with Western medicine treatment 111 for COVID-19 in Wuhan Jinyintan Hospital, which is one of the hospitals receiving most of COVID-19 patients. In the absence of specific drugs for an emerging 112 113 infectious disease, based on the theory of TCM with thousands of years of experience 114 in the prevention and treatment of infectious disease, in particular, accumulated clinical experience of TCM in the SARS in 2003, Chinese medicine (Q-14) was 115 116 developed to clinical application for treatment of COVID-19 in Wuhan, China. Q-14, 117 also known as Huashi Baidu granule, is a compound granules composed of 14

118 Chinese herbs (see supplementary data). The National Health Commission and the 119 National Administration of TCM of the People's Republic of China developed "National clinical practice guideline for COVID-19 in China" (NHC-NATCM-China 120 121 guidelines) (NHC-China, 2020), Q-14 is one of the main Chinese herbal preparations 122 for the treatment of COVID-19 in NHC-NATCM-China guidelines, which was widely used in clinical practice during the outbreak of COVID-19 in Wuhan, China. One of the 123 important ways to improve the international recognition of Chinese herbal medicine 124 125 is to evaluate the clinical efficacy and safety of Chinese herbal medicine with evidence-based medicine (Tang, 2006). 126

127

At the critical moment of the COVID-19 outbreak in Wuhan of China, we conducted a single-center, open label, randomised controlled trial to assess the efficacy and safety of Q-14 in hospitalized adults with laboratory-confirmed COVID-19.

131 132

133 **METHODS**

134 Trial Oversight

In this open-label randomised trial, we recruited patients with COVID-19 from Wuhan Jinyintan Hospital, Wuhan, China. The protocol was designed in compliance with the Declaration of Helsinki, Good Clinical Practice guidelines, and local regulatory requirements. The study protocol had been approved by the Ethics Review Committee of China Academy of Chinese Medical Sciences. The protocol has been registered in China Clinical Trial Registry website (www.chictr.org/cn/, ChiCTR2000030288). All patients had given written informed consent.

142

143 China Academy of Chinese Medical Sciences research group provided the Chinese 144 Medicine composition and Guangdong Yifang Pharmaceutical Co., ltdproduced the 145 compound granules. The results of this trial are reported in accordance with 146 CONSORT (Consolidated Standards of Reporting Trials) guidelines.

147

148 Trial design, randomization, and procedures

149 This study was a single-center, randomised, parallel, open label trial of Q-14 in 150 patients with laboratory confirmed COVID-19. Participants were enrolled by 151 investigators working in Wuhan Jinyintan Hospital. No placebo was used, and 152 compound granules were not masked. SAS 9.4 software was used to generate 153 random sequences in a 1:1 ratioby an independent statistician from China Center for Evidence-Based Traditional Chinese Medicine who was not aware of the trial protocol. 154 155 Two research nurses, used a mobile software program "CLINICALCRS" to apply for randomization number and assigned participants to interventions. All patients 156 accepted standard care in accordance with the NHC-NATCM-China guidelines 157 158 (version 6.0, published on February 18, 2020). Patients in treatment group were 159 given Q-14 the day after randomization, with a dose of 10g (granules), twice daily for 160 14 days continuously. The day of randomization was defined as day 0 and the following days were defined as day 1 to day 14. Investigators, patients and 161 statisticians were no masked to group assignment. The routine care and laboratory 162 163 staff were unaware of the treatment. Research data was recorded using Medroad Cloud Electronic 164 Data Capture System (Jiangsu Famous Medicine Science and Technology Ltd.) Double data entry was carried out by two different 165 166 recorder. Study quality control was executed in three levels, including first level by clinical research associate, second level by independent GCP (Good Clinical Practice) 167 staffs who did not participant in the trial, third level by clinical research management 168 department of China Academy of Chinese Medical Sciences. 169

170

171 Patients

We recruited 204 patients with laboratory confirmed COVID-19 in Wuhan JinyintanHospital during February 27 to March 27, 2020.

174

175 The inclusion criteria included:1) Comply with the diagnostic criteria for general type

176 COVID-19 in the NHC-NATCM-China guidelines (version 6.0); 2) 18 ≤ Aged ≤ 75 years; 3)

177 Agree to participate in the trial, and the patient, the legal guardian or the person in 6 / 30

charge of the medical institution signed the informed consent through papersignature.

180

181 The exclusion criteria included: 1) Critical patients; 2) Patients who cannot guarantee compliance of using Q-14 during the treatment period, or patients who are difficult 182 183 to take medicine by oral or nasal route; 3) Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with 184 COVID-19; 4) Pregnant or parturient women including patient who have a pregnancy 185 plan or a positive urine pregnancy test; 5) Patients with other systemic malignant 186 diseases such as malignant tumors, mental illnesses, etc., which the researchers 187 188 consider unsuitable for participation in the trial; 6) Patients who have been allergic or 189 intolerant to taking Chinese medicine herb.

190

191 The definition of critical patients was in accordance with the disease severity of 192 COVID-19 in "National clinical practice guideline for COVID-19 in China (version 6.0).

193

194 *Outcome and Assessment*

The primary outcome in this trial was conversion time of SARS-CoV-2 viral assay. The secondary outcomes were: 1) The change of 7-point scale; 2) The rate of critical aggravation; 3) Blood routine test outcomes; 4) Blood biochemical test outcomes; 5) Fever recovery time; 6) Symptom improvement; 7) Evaluation of chest CT examination after treatment compared with baseline. Adverse events were reviewed daily to assure the safety of patients.

201

SARS-CoV-2 viral assay for specimens from upper respiratory tract were tested on day 0, and day 7 to 15. If the test resultwas negative, SARS-CoV-2 viral assay would be conducted at least 24 hours later to observe whether there were two consecutive reports of negative result. When there were two consecutive negative results, the patient was defined to a conversion-of-negative ending and the day of the first negative report was determined as the conversion day. The time from day 0 to

208 conversion day was defined as the conversion time.

209

The 7-point scale was a seven-categoryordinal scaleto test the condition and 210 211 prognosis of severity during treatment. It is consisted of the following categories: 1, 212 not hospitalized with resumption of normal activities; 2, not hospitalized, but unable 213 to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal 214 215 high-flow oxygentherapy, noninvasive mechanical ventilation, orboth; 6, hospitalized, requiring ECMO (extracorporeal membrane oxygenation), invasivemechanical 216 ventilation, or both; and 7, death. The 7-point scale was recorded during days 1 to day 217 218 14. The change of 7-point scale was the score difference after treatment when 219 comparing with baseline.

220

The classification of COVID-19 was record on day 0, 1 to 14. The classification included four categories, mild, moderate, severe and critical with the sequence of severity increasing. If the classification changed to critical during days 1 to 14, the patient would be defined as critical aggravation. The rate of critical aggravation patient would be count after treatment.

226

Blood routine test and blood biochemical test outcomes included complete blood cell
count with differential, blood chemistry, Creative protein, hypersensitive C-reactive
protein, amyloid protein, myohemoglobin, hypersensitive troponin,
erythrocyte sedimentation rate, ferroprotein, D-Dimer, interleukin 6, were tested on
day 0, 7, 14.

232

Vital signs were recorded on day 0, 1 to 14. If body temperature had a fever, which was defined as over 37.3°C, we recorded the day when it began to keep stable below 37.3°C to determining fever recovery time.

236

8 / 30

The symptom including cough, fatigue, headache, chest discomfort and sore throat was recorded onday 0 and 14.The disappearance of symptom will be recorded after treatment. The symptom improvement was evaluated by the disappearance rate of the five symptoms.

241

Chest computed tomography examinations were tested on day 0, 14. Two radiologists 242 with at least 20 years working experience reviewed the CT reports and images, who 243 was unaware of the randomization. The judgment of chest CT including: 1) Score of 244 ground glass area; 2) Score of consolidation area; 3) Density change of ground glass 245 imaging manifestation; 4) Density change of consolidation imaging manifestation; 5) 246 247 Overall evaluation of chest CT examination after treatment compared with baseline. 248 To count the score of lesion area, each lung was divided into 10 regions according to 249 anatomy, which were 20 regions for both sides. If the lesion area was over 50% 250 (contained) in one region, it would be judged as 2 point, and if below 50%, it would 251 be judged as 1 point. The range of sores for area was 0 to 40 points. Density change was recorded after treatment as decreased, no-change or increased. Overall 252 253 evaluation of chest CT examination was the case and proportion of improved, 254 no-change, and aggravated patients in each group.

255

In this trial, we recorded the timing, duration, severity, management and
consequence of adverse events, and determined the association with the usage of
study medications. (Annex 1)

259

260 Statistical analysis

The sample size was calculated based on the alternative hypothesis that the hazard ratio of SARS-CoV-2 viral assay negative conversion rate between treatment group and control group during the 14-day trial period was $\theta \neq 1$. It was assumed that the SARS-CoV-2 viral assay negative conversion time followed an exponential distribution. We assumed that the SARS-CoV-2 viral assay negative conversion rate was 0.6 in all

patients within 14 days, and the hazard ratio $\theta = 2$ based on the experience of treatment at the time. The sample size distribution between treatment group and control group was 1:1, the one-side superiority type I error was 0.05, and the type II error was 0.2, that is, the power was 80%. We estimated a total sample size of 204 at the drop-out rate of 15%.

271

272 For primary outcome, the SARS-CoV-2 viral assay negative conversion time, we firstly 273 used Wilcoxon rank sum test to test the difference of SARS-CoV-2 viral assay negative 274 conversion time between treatment group and control group, and gave the medians 275 and IQR (interquartile range). Then, kaplan-Meier method was used to estimate the 276 cumulative negative conversion rate and draw the survival curve, and the negative 277 conversion rate was compared among groups through log-rank test, the median time 278 and 95% CIs (confidence interval) were given, and the hazard ratios was estimated by 279 Cox regression model. Hazard ratios greater than 1 indicated that the negative 280 conversion rate of treatment group was higher than that of control group.

281

282 For secondary outcomes, the change of 7-point scale was tested by Wilcoxon rank 283 sum test. The rate of critical aggravation was tested by Pearson chi-square test. Both 284 blood routine and blood biochemistry outcomes were numerical data, which was 285 tested by t-test for normal distribution data and Wilcoxon rank sum test for 286 non-normal distribution data. Fever recovery time was tested by Wilcoxon rank sum 287 test. For symptom improvements, which meant the disappearance rate of cough, 288 chest tightness, headache, fatigue, and pharynx, we used the Pearson chi-square test. 289 For the chest CT outcome, the score of area and density for both ground glass and 290 consolidation imaging manifestation, and overall evaluation of chest CT examination, 291 were tested by Wilcoxon rank sum test.

292

Safety analyses were based on the patients' actual exposure to treatment. In this study, statistical packages base, Stats, Rcompanion and survival in R version-3.6.2 and

10 / 30

295 SPSS 20.0 were used for statistical analysis and verification.

296

297 Patient and public involvement

298 No patients were involved in the research design and implementation plan. There is

299 no plan to disseminate the result of this trial to study participants.

300

301

302 **RESULT**

303 Patients

Of the 285 patients were assessed from February 27 to March 27, 81 did not meet the eligibility criteria. Remaining 204 patients were randomised with a ratio 1:1 to treatment group and control group. 195 patients were included in the FAS (Full Analysis Set) (99 in treatment group and 96 in control group) (Figure 1).The mean age was 54 years old, and 36.4% was male. Table 1 showed baseline demographic, clinical characteristics of patients in treatment group and control group.

310

311 Primary outcome

Among 195 patients in FAS, 149 (76.4%) patients (71 treatment group, 78 control group) had converted to negative before the cut-off day of analysis, and the remaining 46 patients (28 treatment group, 18 control group) did not arrive a conversion-to-negative result.

316

In the conversion time of SARS-CoV-2 viral assay, there was no significant difference
between treatment group and control group both in FAS and PPS (Per-protocol Set)
(FAS: n=149. Median (IQR): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); Mean rank:
67.92 vs. 81.44; P=0.051. PPS: n=148. Median (IQR): 10.00 (9.00, 11.00) vs. 10.00
(9.00, 11.00); Mean rank: 67.86 vs. 80.46; P=0.068). The average time of conversionto-negative showed some advantage in treatment group (Mean (SD): FAS: 10.01 (1.74)
vs. 10.44(1.49) days. PPS: 10.04 (1.73) vs. 10.44(1.49) days). The median time to

conversion between treatment group and control group showed no significant
difference as well (FAS: 10.00 (9.00-10.00) vs. 10.00 (10.00-11.00) days, HR: 1.165,
95%CI: 0.84-1.61, P=0.27. PPS: 10.00 (9.00-11.00) vs. 10.00 (10.00-11.00) days, HR =
1.15, 95%CI: 0.83-1.59, P=0.31 by log rank test. Figure 2, Figure 3).

We found among the 116 participants with cardiovascular disease who reached conversion-to-negative, the conversion time of SARS-CoV-2 viral assay is significantly shorter in treatment group as compared with control group.(Median (IQR): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); Mean rank: 51.63 vs. 65.61; P=0.022.). The average time of conversion- to-negative showed some advantage in treatment group

(Mean (SD): FAS: 9.85 (1.42) vs. 10.54 (1.56) days). The median time to conversion
between treatment group and control group showed significantly difference (10.00
(9.00-10.00) vs. 10.00 (10.00-11.00) days, HR: 1.484, 95%CI: 1.02-2.15, P=0.023 by
log rank test. Figure 4).

338

339 Secondary outcome

The change of the 7-point scale was similar in the two groups (Median (ICQ): FAS:
-2.00(-3.00-0.00) vs. -2.00(-3.00-0.00), P=0.109. PPS: -2.00(-3.00, 0.00) vs. -2.00(-3.00,
0.00), P=0.232).

343

344 There was no patient turned critical category during the observation.

345

346 There was no significant difference in blood routine test and blood biochemical test.

347

Fever recovery time was shorter in treatment group as compared in control group
(Median (ICQ): FAS: 2.00 (2.00-3.00) vs. 3.00 (1.00-4.00) days, P=0.029. PPS: 2.00
(2.00-3.00) vs. 3.00 (1.00-4.00), P=0.049).

351

The symptom disappearance rate of cough (FAS: 90.7% vs. 79.5%, P=0.045. PPS:
91.7% vs. 79.5%, P=0.028), fatigue (FAS: 88.1% vs. 75.9%, P=0.038. PPS: 87.8% vs.

12 / 30

75.9%, P=0.045), chest discomfort (FAS: 87.0% vs. 67.8%, P=0.015. PPS: 88.5% vs.
67.8%, P=0.009) was significant higher in treatment group. The symptom
disappearance rate of headache (FAS and PPS: 85.7% vs. 83.3%, P> 0.999) and sore
throat (FAS: 82.8% vs. 74.7%, P=0.195. PPS: 81.7% vs. 74.7%, P=0.272) was similar in
the two groups.

359 In chest computed tomography (Chest CT) examinations, the score of ground glass area was significantly lower in treatment group than control group after 360 treatment(Median (ICQ):FAS: 8.50 (5.00-15.25) vs. 14.00 (7.00-21.75) , P=0.031. PPS: 361 9.00 (4.62-16.00) vs. 14.00 (7.00-21.75), P=0.042) with a larger decrease (Median 362 (ICQ):FAS: -5.75 (-11.25- -2.00) vs.-0.75 (-2.12-2.12), P< 0.001. PPS: -6.50 (-11.75-363 364 -2.00) vs.-0.75 (-2.12-2.12), P< 0.001). The density of ground glass area showed a 365 significant decrease in treatment group (FAS: decreased 36 (80.0%), no-change 366 9(20.0%), increased 0 (0%) vs. decreased 17 (51.5%), no-change 15(45.5%), increased 1(3.0%), P=0.007.PPS: decreased 33 (78.6%), no-change 9(21.4%), increased 0 (0%) vs. 367 decreased 17 (51.5%), no-change 15(45.5%), increased 1(3.0%), P=0.013.)Overall 368 evaluation of chest CT examination after treatment compared with baseline showed 369 370 more patients improved in treatment group (FAS: improved69 (85.2%), no-change 12(14.8%), aggravated 0 (0%) vs. improved55 (67.9%), no-change 23(28.4%), 371 372 aggravated 1(3.7%), P=0.008.PPS: improved65 (85.5%), no-change 11(14.5%), aggravated 0 (0%) vs. improved 55 (67.9%), no-change 23(28.4%), aggravated 1(3.7%), 373 P=0.008.)There was no significant difference in score of area and density of 374 375 consolidation manifestation.

376

377 **Safety**

Among 204 patients, a total of 202 cases were analyzed as the safety population (100 treatment group, 102 control groups), as there were two patients who were assigned to treatment group withdraw their informed consent on the day of randomization and having no baseline information. The comparison of recorded adverse events showed there were 14 patients (16 adverse events) in treatment group and 15 patients (23 adverse events)) in control group (Table 2). There were no serious 13/30

adverse events recorded. Diarrhea (n=15) was the most common adverse event in this trial. For patients who happened digestive discomfort, the Q-14 dosage in treatment group adjusted to half dosage daily until the symptom improved. Other adverse events were transient with duration of one to two days.

388

389

390 **DISSCUSION**

391 This clinical trial (conducted during the outbreak of COVID-19 in Wuhan, China) is the 392 first registered randomised controlled trial evaluating administration of Q-14 in 393 hospitalized adult patients with laboratory confirmed COVID-19 in Wuhan, China. 394 These finds provide evidence to support a notable improvement of typical 395 uncomfortable symptoms caused by COVID-19, such as fever, cough, fatigue and 396 chest discomfort. Additional, a significant improvement of Chest CT by a 14-day 397 course of Q-14 administration to the standard care in hospitalized adult patients with 398 COVID-19.

399

400 At present, there is no definite antiviral drug to accelerate the probability of 401 negativeconversion for SARS-CoV-2 (Parvathaneni and Gupta, 2020; Yadav et al, 2020), 402 the development of a vaccine (Torreele, 2020; Wang et al., 2020) appears to be the 403 last straw for prevention and control of COVID-19. The development of new antiviral 404 requires a considerable length of time and effort for drug design and validation. 405 Clearly, not only will this take time, but everything is unknown. Administration of 406 Q-14 did not resultin a significantly higher probability of negativeconversion than 407 standard of care alone in patientsadmitted to hospital with COVID-19, but it is 408 beneficial for the improvement of typical symptoms in COVID-19 patients. 409 Improvement in clinical symptoms is important to reduce the level of discomfort in 410 hospitalized adult patients with COVID-19, at the same time; it is beneficial to relieve 411 depressive or anxiety caused by typical symptoms of COVID-19 patients or medical 412 workers (Elhadi et al., 2020; Wang et al., 2020), such as fever, cough, fatigue and

chest discomfort. In our study, the safety of Q-14 has been fully investigated. No
serious adverse events were reported except for diarrhea (8 cases of treatment group)
or other adverse reactions in some patients, which resolve themselves within a few
days. The overall clinical safety of a 14-day course of Q-14 administration is
documented.

418

On the other hand, we performed a subgroup analysis, an increase the probability of 419 420 negative conversion of SARS-CoV-2 viral assay conferred by the addition of a 14-day course of Q-14 administration to the standard care in hospitalized adult patients with 421 COVID-19 and cardiovascular diseases. Although the results were statistically 422 significant, they were not particularly significant in terms of time (days). This is not 423 424 within our expectation, which is an interesting finding. Although we cannot rule out 425 the possibility of a chance finding, we think it may be related to the following factor. The majority of COVID-19 patients with cardiovascular diseases are hypertensive; 426 Q-14 may have a certain targeted improvement effect on the pathological status of 427 428 hypertension addition of standard care. Molecular docking showed that baicalein and 429 quercetin were the top two compounds of Q14, baicalein had strong affinity for 430 SARS-CoV-2, and quercetin had strong affinity forACE2 3CL that indicated that 431 baicalein and quercetin might play an important role in the treatment of SARS-CoV-2 (Tao et al., 2020) .Future clinical studies with a larger sample are needed to confirm 432 this effect of Q-14. COVID-19 patients with pre-existing cardiovascular diseases 433 experience disproportionately worse outcomes in mortality (Peng et al., 2020; 434 435 Golemi et al., 2020), the findings of this clinical study may provide an effective drug for the prevention and treatment of COVID-19 patients with hypertension. Of course, 436 more rigorous clinical and basic research is needed to validate the speculation. 437

438

439 Chest CT is used for diagnosis of COVID-19, as an important complement to the 440 RT-PCR (reverse-transcription polymerase chain reaction) tests (Ai et al., 2020; Wong 441 et al., 2020). In the early stages of the COVID-19 epidemic, chest CT may be of 442 greater diagnostic value than RT-PCR tests. At the same time, it will be a very 15/30

443 important observational indicator to evaluate the curative effect for therapeutic 444 schedule. Not only that, scientists have proposed a non-invasive and quantitative prognostic tool for predicting poor outcome in patients with COVID-19 based on CT 445 446 imaging (Wu et al., 2020). Our study found that after 14 days of treatment, Q-14 with 447 standard care can significantly improve abnormal chest CT changes of COVID-19 patients, decreased the score of ground glass area (characteristic chest CT change of 448 COVID-19) significantly. This result suggests that Q-14 has an important therapeutic 449 role in alleviating the condition of COVID-19 patients. 450

451

More and more clinical evidence shows the great role of TCM in the prevention and control of COVID-19 (Hu et al., 2020; Xiao et al., 2020; Xiong et al., 2020). From these studies, we have not seen that Traditional Chinese medicine has a direct antiviral effect in clinical practice, but its ability to quickly relieve clinical symptoms may be closely related to the enhancement of the immune ability of the body.

457

458 **LIMITATIONS OF STUDY**

459 Some limitations existed in the present study. First, we did not set up a placebo as a 460 Q-14 control. In the context of the COVID-19 early outbreak in Wuhan, China, many 461 clinical trials related COVID-19 has yet to be better prepared because of Wuhan 462 guarantine, especially for Q-14 placebo. As we did not adopt stratify randomisation 463 according to disease severity, the cases of severe patient showed significant 464 difference between the two groups. This may have greatly influenced the conclusions 465 of this trial, placebo effect of Q-14 cannot be ruled out. Secondly, the open label rather than double blind design, which may be resulted in possibility of biased 466 467 assessments. Thirdly, we began to determine SARS-CoV-2 RNA conversion from the 468 7th day of the intervention, which may have overlooked some patients who have negative conversion of SARS-CoV-2 within 7 days. Finally, the specimens collected in 469 470 our trial for SARS-CoV-2 RNA determination were mostly from the upper respiratory 471 tract rather than bronchoalveolar lavage fluid, which could result in false negative

472 results.

473

474 CONCLUSION AND POLICY IMPLICATIONS

475 The introduction of TCM into the world is a demand of The Times, which is the 476 worldwide urgent demand for TCM. This trial provides evidence to support a notable 477 improvement of typical uncomfortable symptoms caused by COVID-19, such as fever, 478 cough, fatigue and chest discomfort. Additional, a significant improvement of Chest 479 CT by the addition of a 14-day course of Q-14 administration to the standard care in 480 hospitalized adult patients with COVID-19. In the current situation, Q-14 may provide 481 safe and effective option for controlling the spread of COVID-19, or a solution with 482 Chinese characteristics. China's great success in prevention and control of COVID-19 483 has demonstrated the feasibility of Chinese Approach.

484

485 FUNDING

The study was funded by National Key Research and Development Plan for the
Emergency Management of Novel Coronavirus Pneumonia (No. 2020YFC0841500)

489 AUTHOR'S CONTRIBUTION

490 JL,WY contributed equally to this paper and share joint first authorship. JL contributed to the writing on this paper and in charge of the trial management 491 492 during this study. WY contributed to the data cleaning and statistical analysis. YL contributed to the result analysis and modified the study report. CL contributed to 493 494 the data collection organization on-site in Wuhan Jinyint Hospital and carried out the 495 first level quality control. LR contributed to the organization in Wuhan Jinyintan 496 Hospital and communicated with the patients. CZ designed the protocol and finished 497 the trial registration. RH contributed to the data cleaning and assisted the trial 498 management. XS led the data collection and data recording. QM, WL, HL contributed as clinical expert on-site in Wuhan Jinyintan Hospital from protocol designing to 499 implementation. HS contributed to the trial drug coordinating on-site in Wuhan. 500

501 YC,ZZ contributed to randomisation number application. LH, ZY, LZ, BW, GD, YX, BL, 502 CX, YC, YB, JG, JY, JW, WQ, SC, BY, WW, JL, XX, MX, JJ, GW, XC contributed to 503 theimplementation of intervention during this trial.HZ, JS, LL, DL contributed to 504 collect data on-site in Wuhan. LG contributed to finalize the structure of this paper. 505 LH organized the research group and contributed to the overall designing and management of this trialfor the corresponding authorship. 506

ACKNOWLEDGEMENTS 507

508 We thank China National Medical Team of Traditional Chinese Medicine of China 509 Academy of Chinese Medical Sciences (CNMTCM-CACMS Team), who went to Wuhan 510 in the most critical moment for medical aid and with their hard working, we finished 511 this trial. The member of CNMTCM-CACMS Team including Lugi Huang, Cheng Lv, 512 Qing Miao, Wenliang Lv, Hao Li, Huaxin Shi, Lijie Hu, Zhixu Yang, Li Zhang, Bing Wang, 513 Guoju Dong, Yongyue Xian, Bin Li, Zhengi Zhou, Chunyan Xu, Yingying Chen, Yongjun 514 Bian, Jing Guo, Jinliang Yang, Jian Wang, Wensheng Qi, Suping Chen, Yang Chen, Bei 515 Yan, Wei Wang, Jing Li, Xiaolei Xie, Ming Xu, Jianxin Jiang, Gang Wang, Xiaodong Cong, 516 Haoning Zhu, Jiaheng Shi, Luxing Leng, Dongxu Li. Xinghua Xiang and Yunfei Xing 517 assisted the statistical work. Mingjiang Yao, Ping He, Xiao Liang, Ruiyan Cao, Li Li, 518 Benliang Zou, Ning Wang, Shihuan Tang, Min Li, Xunlu Yin, Hao Wang, Chuanzhou 519 Yang, Chunyu Gao, Liying Wang, Yongli Dong, Ming Chen, Lu Zhang, Xu Wei 520 contributed to the data recording.Yang Zhao, Qiaoning Yang, Rui Li,Yingjue Jia,Yu 521 Dong carried out the second level quality control. Hongjun Yang carried out the third 522 level quality control and Yanping Wang contributed to the management of the trial. 523 Xuedong Yang and Chunzhi Li contributed to the CT reports and images review. Meng 524 Wu contributed to the CT review data verifying.

525 **DECLARATION OF COMPETING INTEREST**

526 None.

EXCLUSIVE LICENCE 527

The Corresponding Author has the right to grant on behalf of all authors and does 528 grant on behalf of all authors, a worldwide licence to the Publishers and its licensees 529

18 / 30

- 530 in perpetuity, in all forms, formats and media according to the requirement on
- 531 exclusive licence of the publication.

532 DATA AVAILABILITY STATEMENT

- 533 The data of this article could be shared within six months after the trial complete via
- the Medroad Cloud Electronic Data Capture System (http://cloud.medroad.cn/).

535

536 **References**

Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L.,2020. Correlation of Chest CT and
RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014
Cases. Radiology 296, E32-E40. http://doi: 10.1148/radiol.2020200642.

540 Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J,
541 Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q., 2020. Clinical characteristics of 113
542 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1091.
543 https://doi: 10.1136/bmj.m1091

Elhadi M, Msherghi A, Elgzairi M, Alhashimi A, Bouhuwaish A, Biala M, Abuelmeda S, Khel S, Khaled
A, Alsoufi A, Elmabrouk A, Alshiteewi FB, Alhadi B, Alhaddad S, Gaffaz R, Elmabrouk O, Hamed T.B.,
Alameen H, Zaid A, Elhadi A, Albakoush A., 2020. Psychological status of healthcare workers
during the civil war and COVID-19 pandemic: A cross-sectional study. J Psychosom Res 137,
110221. http://doi: 10.1016/j.jpsychores.2020.110221.

549 Golemi Minga I, Golemi L, Tafur A, Pursnani A., 2020. The Novel Coronavirus Disease (COVID-19) 550 and Its Impact on Cardiovascular Disease. Cardiol Rev 28, 163-176. http://doi: 551 10.1097/CRD.00000000000317.

Hu K, Guan W.J., Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z, Zheng Q, Yang Z, Liang J, 552 553 Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS., 2020. Efficacy and safety of Lianhuaqingwen 554 capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, 555 prospective, randomized controlled trial. Phytomedicine ,153242. http://doi: 556 10.1016/j.phymed.2020.153242.

Li Z, Chen Q, Feng L, Rodewald L, Xia Y, Yu H, Zhang R, An Z, Yin W, Chen W, Qin Y, Peng Z, Zhang T,
Ni D, Cui J, Wang Q, Yang X, Zhang M, Ren X, Wu D, Sun X, Li Y, Zhou L, Qi X, Song T, Gao GF, Feng
Z; China CDC COVID-19 Emergency Response Strategy Team., 2020. Active case finding with case
management: the key to tackling the COVID-19 pandemic. Lancet 396, 63-70. https://doi:
10.1016/S0140-6736(20)31278-2.

562National Health Commission of the People's Republic of China (NHC-China) and National563Administration of Traditional Chinese Medicine of the People's Republic of China, published on564February 18, 2020. National clinical practice guideline for COVID-19 in China (Tentative 6th565edition).February19,2020.

566 <u>http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm</u>

Parvathaneni V, Gupta V., 2020. Utilizing drug repurposing against COVID-19 - Efficacy, limitations,
and challenges. Life Sci 259, 118275. http://doi: 10.1016/j.lfs.2020.118275.

569 Peng Y, Meng K, He M, Zhu R, Guan H, Ke Z, Leng L, Wang X, Liu B, Hu C, Ji Q, Keerman M, Cheng L,

570 Wu T, Huang K, Zeng Q., 2020. Clinical Characteristics and Prognosis of 244 Cardiovascular

571 Patients Suffering from Coronavirus Disease in Wuhan, China. J Am Heart Assoc 9, e016796.
572 http://doi: 10.1161/JAHA.120.016796.

Tang J, 2006. Research priorities in traditional Chinese medicine. BMJ 333, 391-394. http://doi:
10.1136/bmj.333.7564.391.

575 Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J,

576 Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. 2020. Hydroxychloroquine

577 in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised

578 controlled trial. BMJ 369, m1849. https://doi: 10.1136/bmj.m1849

Tao Q, Du J, Li X, Zeng J, Tan B, Xu J, Lin W, Chen X.L., 2020. Network pharmacology and molecular
 docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment

581 of COVID-19. Drug Dev Ind Pharm 46, 1345-1353. http://doi: 10.1080/03639045.2020.1788070.

582 The State Council Information Office of the People's Republic of China. Fighting Covid-19: China in

583 Action. June 7, 2020. http://www.scio.gov.cn/zfbps/32832/Document/1681809/1681809.htm

Torreele E, 2020. The rush to create a covid-19 vaccine may do more harm than good. BMJ 370,
m3209. http://doi: 10.1136/bmj.m3209.

Wang C, Horby P.W., Hayden F.G., Gao G.F., 2020. A novel coronavirus outbreak of global health
concern. Lancet 395, 470-473. https://doi: 10.1016/S0140-6736(20)30185-9.

Wang E.A., Zenilman J, Brinkley-Rubinstein L, 2020. Ethical Considerations for COVID-19 Vaccine
 Trials in Correctional Facilities. JAMA 324, 1031-1032. http://doi: 10.1001/jama.2020.15589.

Wang W, Song W, Xia Z, He Y, Tang L, Hou J, Lei S., 2020. Sleep Disturbance and Psychological
Profiles of Medical Staff and Non-Medical Staff during the Early Outbreak of COVID-19 in Hubei
Province, China. Front Psychiatry 11, 733. http://doi: 10.3389/fpsyt.2020.00733.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li
H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W,
Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki
T, Hayden FG, Horby PW, Cao B, Wang C., 2020. Remdesivir in adults with severe COVID-19: a
randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569-1578.
https://doi: 10.1016/S0140-6736(20)31022-9.

World Health Organization (WHO), Coronavirus disease 2019 (COVID-19) Weekly Epidemiological
Update. August 24, 2020.

601 <u>https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200824-weekly-epi-up</u>
 602 <u>date.pdf?sfvrsn=806986d1_2</u>

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S,
Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y., 2020.
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With
Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 180, 934-943.

607 https://doi: 10.1001/jamainternmed.2020.0994

Wong H.Y.F., Lam H.Y.S., Fong A.H., Leung S.T., Chin T.W., Lo C.S.Y. Lui M.M., Lee J.C.Y., Chiu K.W.,
Chung T.W., Lee E.Y.P., Wan E.Y.F., Hung I.F.N., Lam T.P.W., Kuo M.D., Ng M.Y.,2020. Frequency and
Distribution of Chest Radiographic Findings in Patients Positive for COVID-19. Radiology 296,
E72-E78. http://doi: 10.1148/radiol.2020201160.

612 Wu Q, Wang S, Li L, Wu Q, Qian W, Hu Y, Li L, Zhou X, Ma H, Li H, Wang M, Qiu X, Zha Y, Tian J.,2020.

Radiomics Analysis of Computed Tomography helps predict poor prognostic outcome in COVID-19.
Theranostics 10, 7231-7244. http://doi: 10.7150/thno.46428.

Xiao M, Tian J, Zhou Y, Xu X, Min X, Lv Y, Peng M, Zhang Y, Yan D, Lang S, Zhang Q, Fan A, Ke J, Li X,
Liu B, Jiang M, Liu Q, Zhu J, Yang L, Zhu Z, Zeng K, Li C, Zheng Y, Wu H, Lin J, Lian F, Li X, Tong
X.,2020. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment
of COVID-19: A randomized controlled trial. Pharmacol Res 161,105126. http://doi:
10.1016/j.phrs.2020.105126.

Kiong X, Wang P, Su K, Cho W.C., Xing Y.,2020. Chinese herbal medicine for coronavirus disease
2019: A systematic review and meta-analysis. Pharmacol Res 160,105056. http://doi:
10.1016/j.phrs.2020.105056.

Yadav M, Dhagat S, Eswari J.S., 2020. Emerging strategies on in silico drug development against
COVID-19: challenges and opportunities. Eur J Pharm Sci 155, 105522. http://doi:
10.1016/j.ejps.2020.105522.

627 Figure legend

- 628 Figure 1. Research flow chart
- Figure 2. Time to conversion analysis of SARS-CoV-2 viral assay and
- 630 conversion ending (n=149, FAS)
- Figure 3. Time to conversion analysis of SARS-CoV-2 viral assay and
- conversion ending (n=148, PPS)
- Figure 4. Time to conversion analysis of SARS-CoV-2 viral assay and
- 634 conversion ending, in participants with cardiovascular disease who
- reached negative conversion (n=116)

636







672 673



Characteristics	Treatment group (n=99)	Control Group (n=96)	Total (n=195)		
Median (IQR))age, years	56.00 (48.50-62.00)	56.00 (48.50-62.00)	56.00 (48.50- 62.00)		
SEX	SEX				
Male	36 (36.4%)	37 (38.5%)	73 (37.4%)		
Disease severity					
Mild and Moderate	74 (74.7%)	89(92.7%)	163 (83.6%)		
Severe	25 (25.3%)	7 (7.3%)	32 (16.4%)		
Coexisting condition					
Hyperten sion	63 (63.6%)	54 (56.2%)	117 (60.0%)		
Hyperlipemi a	6 (6.1%)	10 (10.4%)	16 (8.2%)		
Coronary heart disease	7 (7.1%)	3 (3.1%)	10 (5.1%)		
Thyroid disorder	1 (1.0%)	1 (1.0%)	2 (1.0%)		
Cerebral lacunar infarction	1 (1.0%)	3 (3.1%)	4 (2.1%)		
Diabetes	18 (18.2%)	9 (9.4%)	27 (13.8%)		
Rheumatoid disease	2 (2.0%)	1 (1.0%)	3 (1.5%)		
Chronic bronchitis	1 (1.0%)	1 (1.0%)	2 (1.0%)		
Symptoms					
Fever	85 (85.9%)	90 (93.8%)	175 (89.7%)		
Cough	86 (86.9%)	73 (76.0%)	159 (81.5%)		
Fatigue	84 (84.8%)	87 (90.6%)	171 (87.7%)		
Headache	14 (14.1%)	12 (12.5%)	26 (13.3%)		
Chest discomfort	54 (54.5%)	59 (61.5%)	113 (57.9%)		
Sore throat	87 (87.9%)	87 (90.6%)	174 (89.2%)		
Laboratory parameters—Median(IQR)/mean	n (SD)				
White blood cell count, ×10 ⁹ /L	5.84 (4.90- 7.29)	5.68 (4.78- 6.75)	5.77 (4.82- 6.89)		
Red blood cell count, $\times 10^{12}$ /L	4.13 (3.84- 4.44)	4.04 (3.67-4.35)	4.06 (3.76- 4.39)		
Platelet count, ×10 ⁹ /L	229.00 (172.00- 267.50)	212.00 (184.75-261.75)	222.00 (179.50- 265.50)		
Hemoglobin, g/L	125.00 (118.00- 135.50)	122.50 (111.00- 133.50)	124.00 (116.00- 135.00)		
Neutrophil count, ×10 ⁹ /L	3.66 (2.69- 4.43)	3.28 (2.61-4.19)	3.42 (2.67- 4.35)		
Lymphocyte count, ×10 ⁹ /L	1.73 (1.48- 2.02)	1.65 (1.38- 2.07)	1.68 (1.42- 2.05)		
Monocyte count, ×10 ⁹ /L	0.41 (0.35- 0.49)	0.38 (0.32- 0.46)	0.40 (0.34- 0.48)		
Neutrophil percentage, %	59.30 (54.35- 65.55)	58.85 (50.53-64.10)	59.10 (52.60-65.20)		
Lymphocyte percentage, %	30.17 (8.41)	30.27 (9.54)	30.22 (8.96)		
Monocyte percentage, %	7.20 (6.10- 7.80)	6.80 (5.88- 7.85)	7.00 (6.00- 7.80)		
Total bilirubin, umol/L	12.20 (10.00- 15.55)	11.90 (9.80- 14.88)	12.10 (9.85- 15.25)		

Table 1 | Baseline demographic and clinical characteristics of patients in FAS

Alanine transaminase, U/L	25.00 (19.00- 37.50)	27.50 (19.00- 35.00)	26.00 (19.00- 35.00)
Glutamic oxalacetic transaminase, U/L	25.00 (22.00- 31.00)	29.00 (23.00- 34.00)	26.00 (22.00- 33.00)
Albumin, g/L	39.40 (37.25- 40.85)	39.10 (37.20-40.50)	39.20 (37.20- 40.70)
Urea, mmol/L	4.50 (3.65- 5.23)	4.57 (3.60- 5.50)	4.54 (3.60- 5.37)
Creatinine, umol/L	62.40 (53.50-73.90)	64.60 (56.50-73.10)	63.00 (54.65- 73.90)
Blood glucose, mmol/L	5.20 (4.80- 6.05)	5.10 (4.80-6.12)	5.20 (4.80- 6.10)
Creatine kinase, U/L	63.00 (45.25- 85.75)	65.50 (50.00-95.00)	63.50 (48.00- 87.00)
Creatine kinase isoenzyme, U/L	10.00 (8.00- 12.00)	11.00 (8.00- 12.25)	10.00 (8.00- 12.00)
Blood potassium, mmol/L	4.20 (4.00- 4.50)	4.30 (4.00- 4.50)	4.30 (4.00- 4.50)
Blood sodium, mmol/L	140.00 (139.00- 141.00)	140.00 (138.00- 142.00)	140.00 (138.00- 142.00)
Blood chlorine, mmol/L	106.00 (104.00-108.00)	106.00 (104.00-107.00)	106.00 (104.00- 107.00)
C-reactive protein, mg/L	1.00 (0.50- 2.90)	1.00 (0.60- 1.70)	1.00 (0.50- 2.38)
Hypersensitive C-reactive protein, mg/L	1.10 (0.50- 2.00)	1.10 (0.50- 2.80)	1.10 (0.50-2.35)
Amyloid protein, mg/L	3.70 (3.70- 6.45)	3.70 (3.70- 5.75)	3.70 (3.70- 6.15)
Myoglobin, ng/mL	30.60 (24.70- 42.40)	32.40 (24.95-41.85)	31.00 (24.80-41.92)
Hypersensitive troponin, pg/mL	1.50 (0.70- 3.40)	1.70 (0.70- 3.20)	1.70 (0.70-3.40)
Blood sedimentation, mm/h	15.00 (7.00- 23.00)	16.00 (11.00- 25.00)	16.00 (9.00- 25.00)
Ferritin, ng/mL	196.43 (128.24- 309.99)	195.99 (114.96- 300.11)	195.99 (119.33- 309.75)
D-dimer, ug/mL	0.38 (0.23- 0.65)	0.44 (0.24- 0.84)	0.40 (0.24- 0.76)
Interleukin 6, pg/mL	7.02 (5.46- 8.59)	6.78 (5.73- 8.43)	6.94 (5.54- 8.54)
Procalcitonin , ng/ml	0.05 (0.05- 0.05)	0.05 (0.05- 0.05)	0.05 (0.05- 0.05)
Chest CT parameters—Median(IQR)			
score of ground glass area	16.50 (10.25-21.75)	17.00 (8.00-27.50)	16.75 (9.00-24.12)
Score of consolidation area	0.00 (0.00- 0.00)	0.00 (0.00-0.00)	0.00 (0.00-0.00)

680

_

Adverse events	Treatment group (n=100)	Control Group (n=102)	Total (n=202)
All adverse even	16	23	35
Diarrhea	8 (8%)	7 (6.9%)	15 (7.4%)
Abdominal discomfort	2 (2%)	7 (2%)	5 (2.5%)
Decreased appetite	3 (3%)	O (O)	3 (1.5%)
Anxiety	0 (0)	2 (2.0%)	2 (1.0%)
Oral ulcer	1(1%)	1 (1.0%)	2 (1.0%)
short breath	0 (0)	2 (2.0%)	2 (1.0%)
Constipation	0 (0)	1 (1.0%)	1 (0.5%)
Vomiting	1 (1%)	O (O)	1 (0.5%)
ltchy skin	0 (0)	1 (1.0%)	1 (0.5%)
Lower extremity edema	0 (0)	1 (1.0%)	1 (0.5%)
Dry eye	1 (1%)	O (O)	1 (0.5%)
Limb pain	O (O)	1 (1.0%)	1 (0.5%)

Table 2 | Summary of adverse events in safety population*

*Values stand for numbers (percentages of patient happened adverse events)

683

684 Annex 1 Research Period

Day 0 (Randomization and baseline)

Day	1 (start the intervention)	Day 7 Blood test	Day 14 Blood test CT	Day 15
		, ,	Clinical cl	SARS-CoV-2 viral assay assification and 7-point scale al signs

sinn — n-octolycus — indecidentycus













sinn — vertagae — isoscherigter





